Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)

0 avis

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)

Archive ouverte

Edité par CCSD ; Karger -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia

Archive ouverte | Bernard, Valérie | CCSD

International audience. BACKGROUND: Refractory hypoglycemia in patients with metastatic insulinoma is an important cause of morbidity and mortality. Everolimus could be a new therapeutic option.METHODS: Within the F...

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours

Archive ouverte | Lepage, Come | CCSD

International audience. IntroductionPatients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Patients (...

Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study

Archive ouverte | Legoux, Jean-Louis | CCSD

International audience

Chargement des enrichissements...